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Am J Med Genet Part A 9999A:1–6.Bohring–Opitz syndrome (BOS) was first described by Bohr-
ing et al. [1999]. The authors reported four cases which had
several features in common, including a prominent metopic
suture, hypertelorism, exophthalmos, cleft lip and palate,
limb anomalies, as well as difficulty feeding with severe
developmental delays. In almost 50% of cases that meet
the clinical criteria for BOS, de novo frameshift and nonsense
mutations in the ASXL1 gene have been detected, suggesting
that loss of function of this gene is a major cause. We report
on the clinical characterization of one young female patient
who was evaluated because of severe developmental delays,
failure to thrive, and multiple minor anomalies and was
clinically diagnosed with BOS. Whole exome sequencing
analysis detected one novel disruptive frameshift mutation
in the ASXL1 gene and we were also able to confirm the
presence of two CFTR mutations associated with her chronic
pancreatitis with acute severe breakthrough attacks requiring
multiple ICU admissions. This latter complication of pancre-
atitis further contributed to the complexity of the clinical
presentation and represents an independent genetic finding.
Our case report emphasizes the importance of highly specific
phenotypic characterization of patients with complex phe-
notypes before proceeding with molecular studies. That
approach will lead to more accurate molecular data interpre-
tation and better clinical genetic diagnosis, particularly for
those patients with rare, difficult-to-diagnose disorders.
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In 1999, Bohring et al. reported on four cases with prominent
metopic suture, hypertelorism, exophthalmos, cleft lip and palate,
limb anomalies, feeding difficulty and severe developmental delays
[Bohring et al., 1999].2015 Wiley Periodicals, Inc.Later on, diagnostic criteria were defined for the diagnosis of
Bohring–Opitz syndrome (BOS), based on the most common
phenotypic manifestations. These diagnostic criteria are micro-
cephaly, trigonocephaly, palatal abnormalities, prominent eyes and
hypoplastic supraorbital ridges, upslanting palpebral fissures,
depressed nasal bridge and anteverted nares, facial nevus flam-
meus, low-set, posteriorly angulated ears, failure to thrive, and
severe developmental delays. Other minor anomalies may also be
observed in patients with BOS, including low frontal and temporal
hairline with hirsutism, hypertelorism, exophthalmos and retro-
gnathia [Hastings et al., 2011].
Patients with BOS have a particular and characteristic limb
posture, described as the “BOS posture”, which consists of the
external rotation and/or adduction of shoulders, with flexion at the
elbows andwrists and ulnar deviation of the wrists and/or fingers at
the level of the metacarpophalangeal (MCP) joint [Magini et al.,
2012]. Also, in some cases, the patients with BOS have severe
scoliosis.1
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in comparison with their length, leading to central obesity [Pierron
et al., 2009]. Systemic manifestations which are nonspecific but
may be associated with BOS include cardiac anomalies in approxi-
mately 50% of cases. The most frequent are atrial septal defects,
patent ductus arteriosus, and valvular abnormalities (most com-
monly pulmonary stenosis). Gastrointestinal anomalies may
include intestinal malrotation and inguinal hernias among others.
Ophthalmologic manifestations comprise strabismus and retinal
abnormalities which are observed in up to 50% of cases and, to a
lesser extent, anterior chamber abnormalities (20%) and myopia
(33%).
Finally, 70% of patients have structural brain abnor
malities. Among those, ventriculomegaly, delayed myelination,
Dandy–Walker malformation, generalized atrophy involving the
corpus callosum and brainstem, and neuronal migration abnor-
malities have been described. Seizures may be present in some
patients [Hastings et al., 2011].
Life expectancy in BOS patients is decreased because they are
more prone to infections and they may experience cardiac arrhyth-
mias and/or apneas. Moreover, previous reports on BOS describe a
high rate of infant mortality (40%), which is directly correlated
with the previously described complications [Russell and Graham,
2013].
The molecular basis of BOS was recently identified, making
molecular diagnosis possible [Hoischen et al., 2011]. For almost
50% of cases that meet the clinical criteria for BOS, de novo
frameshift and nonsense mutations in the ASXL1 gene have
been detected. This suggests that the molecular correlation is
loss of function of this gene, although, from amore comprehensive
perspective, other putative genes might be involved. Moreover,
upon further review on the literature, we observed that some
reported cases with the typical phenotype did not carry mutations,
suggesting genetic heterogeneity.
The ASXL1 gene, which is located at HSA 20q11.21, encodes the
additional sex combs–like protein 1, which contains 1,543 amino
acids. This protein belongs to the polycomb group (PcG) and
trithorax complexes family. Polycomb group genes are involved in
chromatin based gene silencing, while trithorax group genes
counteract the silencing effects of chromatin to maintain gene
activity, suggesting that additional sex combs–like protein 1 is
required for maintenance of both activation and silencing ofHOX
genes, which are involved in body patterning, as well as in chro-
matin remodeling [Fisher et al., 2003].
To date, current literature reports a total of 9 patients who have
been clinically diagnosed with BOS, and confirmed by molecular
analysis of ASXL1.
Magini et al. [2012] reported on two unrelated patients with
Bohring–Opitz syndrome confirmed by molecular analysis. One
was a female patient that presented with congenital microcephaly
and hypotonia. The patient displayed typical facial features, in-
cluding frontal bossing, facial nevus flammeus, prominent eyes,
hypertelorism, mild hirsutism low-set, posteriorly rotated ears,
long philtrum, highly arched, narrow palate, and everted lower lip.
Additionally, she presented abnormal posture with elbow contrac-
tures. Systemic manifestations included failure to thrive, severe
myopia and seizures. CNS malformation was demonstrated bybrainMRIwhich showed dilatation of lateral ventricles,mildly thin
corpus callosum, and apparent moderate atrophy of the spinal
cord. By 3 years of age the patient was noted to have mild
hepatomegaly and thoracolumbar scoliosis. She had severe psy-
chomotor retardation and she was still nonverbal. An unrelated
affected male presented with trigonocephaly secondary to partially
fused metopic suture, a facial capillary hemangioma and upslant-
ing palpebral fissures, prominent eyes with hypoplastic supraor-
bital ridges, highly arched, narrow palate, low-set ears, marked
hirsutism and short neck. This patient also presented with truncal
hypotonia, scoliosis, cryptorchidism, and the typical BOS posture
with contractures of the hips, knees, and ankles, as well as talipes
valgus deformity of the feet. In terms of systemic manifestations,
the patient had feeding difficulties with failure to thrive and
myopia. Brain MRI showed enlarged cerebral ventricles, hypo-
myelination of the periventricular white matter and a hypoplastic
corpus callosum. At around 7 years of age, the boy had severe
neurodevelopmental delay and he was nonverbal although he was
able to communicate through images, letters, and signs, and had
social interaction as well.
Hoischen et al. [2011] reported 13 patients who clinically
met the diagnostic criteria established by Bohring et al. The
majority of cases were infants. In this series, 7 out of 13 patients
were found to have mutations in the ASXL1 gene. Two of the
seven patients reached adult age (only one of those two patients,
a 24 year-old, is mentioned and picture illustrated five more
subjects, who were children up to 11 years of age). The fact that
only 7 out of 13 subjects had ASXL1 mutations, suggested that
mutations or structural alterations in other genes may cause this
syndrome.
Kaname et al. [2007] reported a mutation in CD96 in a patient
with diagnosis of C syndrome based on typical clinical features,
including unusual facies, wide alveolar ridges, multiple buccal
frenula, limb defects, visceral anomalies, redundant skin, psycho-
motor retardation, and hypotonia. They sequenced CD96, which
was associated with a phenotype resembling Opitz C-syndrome, in
nine karyotypically normal Japanese patients with a clinical diag-
noses of the C or C-like syndrome. Two of the patients were
reported as having C-like syndrome, which displays some pheno-
typic overlap with Bohring-Opitz syndrome. In the remaining
patients, neither deletions nor mutations were identified in two
candidate genes(CD96 and ZEBD2). Moreover, at some point,
BOS was proposed as the most severe end of the same clinical
spectrum which includes C-syndrome but always manifests with
exophthalmos.
Bainbridge et al. [2013] identified four individuals with de novo
truncation mutations in a related gene, ASXL3 (chromosome 18).
In all four families, the affected children displayed features of BOS.
Dysmorphic features consisted of arched eyebrows, anteverted
nares, and ulnar deviation of the hands. These features overlap
with Cornelia de Lange Syndrome (CdLS) and BOS, except that
these patients did not present with trigonocephaly, which is
characteristic of BOS. Systemic manifestations included severe
postnatal growth retardation, difficulty feeding and severe psycho-
motor delay.
Of note, ASXL3 is in the same gene family as ASXL1 and
mutations in ASXL3 are known to be associated with a disorder
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individuals was variable in terms of presentation and severity, a
phenomenon that is also associated with ASXL1 mutations and is
currently under study (Fig. 1).
A more recent report described a heterozygous frame shift
variant in the additional sex combs-like 3, (ASXL3) gene on a
proband who also displayed considerable overlap with the BOS
phenotype [Dinwiddie et al., 2013]. Dinwiddie et al. reported a
6 year-old, nonverbal African American with craniosynostosis,
prominent eyes, global developmental delay and autism, although
this patient did not present with flammeus nevus, micro- or
retrognathia, abnormal palate and the typical BOS posture. This
was the second report and fifth patient with pathogenic mutations
in ASXL3. The authors conclude that truncating frameshift
mutations in the ASXL3 gene phenotypically correlate with a
distinct disorder that shares significant clinical features with
Bohring–Opitz syndrome and is characterized by craniofacial
anomalies and global developmental delay.
In terms of inheritance, although the large majority of reported
cases are sporadic, Greenhalgh et al. [2003] described a brother
and sister with Bohring–Opitz syndrome, suggesting the possibility
of autosomal recessive inheritance or germ line mosaicism
[Greenhalgh et al., 2003].
We report on the clinical characterization of one young adult
female patient who was recently diagnosed with BOS and pancrea-
titis in whomwe detected a novel disruptive frameshiftmutation in
ASXL1 and two CFTR mutations (c.1521_1523delCTT;p.F508del
and c.958T>G; p.L320V).Clinical Report
Our patient is a 17 year-old girl who was born at term with a birth
weight of 2500 g to a 35 year-old G3P2 mother. She was born to
non-consanguineous Caucasian parents. Pregnancy was compli-
cated by IUGR. She presented with a post-natal history of
profound neurodevelopmental delay and failure to thrive. Feed-
ing was a significant problem, with pharyngeal dysphagia andFIG. 1. Our patient with ASXL1 mutation. This picture depicts our patient’
hypertelorism, synophrys, upslanting palpebral fissures, some degree of egastro-esophageal reflux. She required Nissen fundoplication and
gastrostomy. She also presented with severe scoliosis requiring
spinal fusion surgery, and dysfunctional uterine bleeding. Her
care was further complicated by intestinal resection following
volvulus necessitating ostomy and by chronic pancreatitis with
severe recurrent acute episodes requiring admission to the in-
tensive care unit. She had a negative family history for congenital
abnormalities and pancreatitis.
The patient was microcephalic (HC< 3rd centile), her height
was below the 3rd centile and her weight was on the 10th centile.
She had a “triangular” face, hypertelorism, low anterior hairline,
synophrys, upslanting palpebral fissures, some degree of exoph-
thalmos, flat nasal bridge, anteverted nares, low set ears, small
mouth, wide spaced teeth, retrognathia, finger pads, thoracic
scoliosis, was wheelchair-dependent, with hypermobile joints fixed
flexion contractures of both wrists and fingers as well as flexion
contractures of her legs and feet.
The patient was non-verbal, did not track objects and did not
follow commands. Neurologic exam revealed tremor and chorei-
form movements. CAT scan of the head revealed cerebral volume
loss and ventriculomegaly. EEG revealed mild diffuse slowing
suggestive of underlying multifocal cerebral dysfunction, as well
as frequent multifocal and generalized spike and wave discharge.
Abdominal ultrasound showed bilateral renal cysts and splenic
cysts. Also, she presentedwith longQTon an EKG.Previous genetic
work up included normal karyotype, SNP microarray and molec-
ular analysis of SPINK1 for pancreatitis.MATERIALS AND METHODS
Exome sequencing was performed on DNA obtained from the
peripheral blood of the patient. Briefly, exome sequencing libraries
were prepared from genomic DNA from the proband and the
parents using Agilent SureSelect XT Human All Exome v5þUTRs
kit according to the manufacturers’ protocol. Paired-end sequenc-
ing was performed on the Illumina HiSeq 2500 platform to provide
a mean sequence coverage of more than 150X, with more thans most prominent facial features including: triangular face,
xophthalmos, low set ears and wide spaced teeth.
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were analyzed and annotated using Nextgene (Softgenetics,
LLC. PA) software, an in-house developed “pipeline” for clinical
interpretation.
RESULTS
Exome sequencing analysis revealed a two base pair deletion
(c.4116_4117delTT) in the ASXL1 gene that results in a frameshift
(p.F1373fs). Sanger sequencing of the patient and parental DNA
specimens confirmed the variant to be de novo. In addition to the
pathogenic ASXL1 variant identified in this patient, exome
sequencing confirmed the presence of two heterozygous changes
in CFTR (c.1521_1523delCTT; p.F508del and c.958T>G;
p.L320V) which were detected by CF testing.
Based on the previously described clinical picture, our patient
most likely has Bohring–Opitz syndrome, which is known to be
autosomal dominant, the patient also is a compound heterozy-
gote for the CFTR gene. This genetic finding explains the chronic
and the recurrent severe pancreatitis that she had from early
childhood.
Genetic counseling was provided. The de novo nature of the
ASXL1 mutation was explained as was the very low, but not
negligible, recurrence risk due to the possibility of gonadal mosai-
cism. The inheritance of CFTR mutations was explained and the
25% recurrence risk was reviewed. Testing for theCFTRmutations
was offered to the family.TABLE I. Prevalence of ASXL1 Mutation Based on C
Clinical features ASXL1 mutation n /%
Feeding difficulties 8/8 (100)




Prominent eyes 9/9 (100)
Trigonocephaly 8/9 (89)
Microcephaly 9/9 (100)
Nevus flammeus 8/9 (89)
Micro/retrognathia 8/9 (89)
Depressed nasal bridge 4/8 (50)
Low-set ears 6/9 (67)
Upslanting palp. fissures 6/9 (67)
Broad alveolar ridges 7/8 (87)
Anteverted nares 4/8 (50)
Hypertelorism 5/9 (55)
Low hairline 6/9 (67)
Hirsutism 8/9 (89)
BOS posture 9/9 (100)
Brain abnormalities 7/9 (78)
Fixed contractures 8/9 (89)
Hypotonia 7/9 (78)
Renal abnormalities 2/9 (22)
Modified from Magini et al. [2011].DISCUSSION
A summary of clinical features of our patient and previously
reported ASXL1-positive BOS cases are in Tables I, II and III.
Our patient was initially evaluated regarding severe developmental
delay, failure to thrive, and minor anomalies. Her clinical picture
was complicated by chronic pancreatitis. Exome sequencing
revealed a de novo frameshift mutation in ASXL1, which was
predicted to be pathogenic. This mutation is associated with
Bohring-Opitz syndrome which is consistent with our patient’s
phenotype.
De novo truncating and/or frameshift mutations in ASXL1 are
associated with Bohring–Opitz syndrome [Bainbridge et al., 2013].
Although the variant identified in this patient has not been
previously reported, it was predicted to abolish the Zinc finger
domain of the protein that is essential for the normal function of
ASXL1 and is considered pathogenic.
ASXL1 [Katoh, 2013] encodes a chromatin-binding protein
required for normal determination of segment identity in the
developing embryo. The protein is a member of the Polycomb
group of proteins, which are implicated in embryogenesis and
carcinogenesis through transcriptional regulation of target genes.
The ASXL1 protein is thought to disrupt chromatin in localized
areas, enhancing transcription of certain genes while repressing the
transcription of other genes. The protein encoded by this gene
functions as a ligand-dependent co-activator for retinoic acid
receptor in cooperation with nuclear receptor co-activator.linical Features in Patients Diagnosed With BOS
No ASXL1 mutation n /% ASXL1 mut. n/% with our case
6/6 (100) 9/9 (100)
6/6 (100) 9/9 (100)
4/6 (67) 9/10 (90)
3/6 (50) 6/9 (70)
0/4 (0) 3/9 (33)
6/6 (100) 10/10 (100)
5/6 (83) 9/10 (90)
5/6 (83) 10/10 (100)
6/6 (100) 9/10 (90)
6/6 (100) 9/10 (90)
5/6 (83) 5/9 (55)
5/6 (83) 7/10 (70)
3/6 (50) 7/10 (70)
5/5 (100) 8/9 (88)
4/5 (80) 5/9 (55)
5/6 (83) 6/10 (60)
3/6 (50) 7/10 (70)
1/6 (17) 9/10 (90)
6/6 (100) 10/10 (100)
4/6 (67) 8/10 (80)
4/6 (67) 9/10 (90)
4/6 (67) 8/10 (80)
2/6 (33) 3/10 (30)
TABLE II. Prevalence of Clinical Features That are Not Present in our Case Compared to Previous BOS Reports
Features not present in our case ASXL1 mutation No ASXL1 mutation
Recurrent infections 5/8 (62) 4/5 (80)
Cardiac abnormalities 3/9 (33) 2/6 (33)
Apneas 4/8 (50) 1/4 (25)
Genital abnormalities 2/9 (22) 2/6 (33)
Cleft palate 3/9 (33) nr
Epicanthal folds 2/9 (22) 1/6 (17)
Modified from Magini et al. [2011].
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although not confirmed by molecular identification of the causa-
tive mutation [Oberklaid and Danks, 1975; Bohring et al., 1999;
Hastings et al., 2011]. Current molecular diagnostic methods lead
to better definition of this syndrome by making a more accurate
phenotypical-genotype correlation.
Only 10 cases (including the two previous reports and our
report) of clinically diagnosed BOS have been confirmed by
molecular analysis of theASXL1 gene, as per current literature.
All cases (100%) present with feeding difficulties, severe/profound
learning disability, prominent eyes, microcephaly and the typical
BOS posture. Also, most of cases (80 to 90%) present with IUGR,
trigonocephaly, nevus flammeus during early infancy, low-set ears,
broad alveolar ridges, micro/retrognathia, fixed contractures, hir-
sutism, hypotonia and brain abnormalities. Additionally, a high
percentage of cases (60 to 80%) present with upslanting palpebral
fissures and low hairline, recurrent infections and seizures.
Four patients are described with a BOS phenotype but lacking
mutations in the ASX1 gene but with pathogenic mutations in
ASXL3. The clinical features of these four patients include severe
feeding difficulties present from birth (3/4), severe post-natal
growth retardation and severe psychomotor delay (4/4). Physical
findings include small size at birth (3/4), microcephaly (3/4),
high and broad forehead, periorbital fullness, arched eyebrows,TABLE III. Most Frequent Features in BOS











Modified from Magini et al. [2011].anteverted nares, ulnar deviation of the hands (3/4) and high
arched palate (3/4). Of note, none of those patients with ASXL3
mutations, presentedwith trigonocephaly, nevus flammeus, prom-
inent eyes, broad alveolar ridges, hirsutism or the typical ‘BOS
posture’ of elbow and wrist flexion, features that are common for
most patients with ASXL1 mutations.
A more recent report on ASXL3mutations (which is the second
report and fifth patient with pathogenic mutations in ASXL3)
mentions trigonocephaly, prominent eyes, and metopic cranio-
synostosis, microcephaly, upslanting palpebral fissures, and low set
ears, which further contribute to the phenotypic overlap with BOS,
although the patient did not present with flammeus nevus, hirsut-
ism, broad alveolar ridges and typical BOS posture.
Patients with known ASXL3 mutations, represent an overlap-
ping but distinct entity fromBOS, since they donot fully display the
most common features of this latter condition.
In summary, we review the most prevalent phenotypic features
among the patients who have a clinical diagnosis of BOS and were
further confirmed bymolecular analysis (ofASXL1mutation). Our
case report emphasizes the importance of highly specific pheno-
typic characterization of patients before proceedingwithmolecular
studies which will lead to more accurate molecular data interpre-
tation and better clinical genetic diagnosis, particularly for those
patients with rare, difficult-to-diagnose disorders.Cases With ASXL1 Mutation Detected
ses 60 to 80% of cases
Recurrent infections
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